Mural Oncology PLC (MURA)
3.83
+0.01
(+0.26%)
USD |
NASDAQ |
May 03, 16:00
3.83
0.00 (0.00%)
After-Hours: 20:00
Mural Oncology Enterprise Value: -206.04M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 03, 2024 | -206.04M |
May 02, 2024 | -206.21M |
May 01, 2024 | -206.88M |
April 30, 2024 | -208.24M |
April 29, 2024 | -208.24M |
April 26, 2024 | -210.27M |
April 25, 2024 | -211.12M |
April 24, 2024 | -209.93M |
April 23, 2024 | -208.92M |
April 22, 2024 | -210.10M |
April 19, 2024 | -210.44M |
April 18, 2024 | -210.44M |
April 17, 2024 | -207.22M |
April 16, 2024 | -204.68M |
April 15, 2024 | -201.64M |
April 12, 2024 | -199.44M |
April 11, 2024 | -198.08M |
April 10, 2024 | -201.13M |
April 09, 2024 | -200.28M |
April 08, 2024 | -199.61M |
April 05, 2024 | -197.58M |
April 04, 2024 | -193.01M |
April 03, 2024 | -194.19M |
April 02, 2024 | -190.81M |
April 01, 2024 | -188.78M |
Date | Value |
---|---|
March 28, 2024 | -188.10M |
March 27, 2024 | -187.09M |
March 26, 2024 | -194.87M |
March 25, 2024 | -197.75M |
March 22, 2024 | -194.53M |
March 21, 2024 | -196.90M |
March 20, 2024 | -196.39M |
March 19, 2024 | -194.36M |
March 18, 2024 | -190.47M |
March 15, 2024 | -189.45M |
March 14, 2024 | -190.41M |
March 13, 2024 | -184.40M |
March 12, 2024 | -184.23M |
March 11, 2024 | -182.56M |
March 08, 2024 | -180.73M |
March 07, 2024 | -179.73M |
March 06, 2024 | -181.23M |
March 05, 2024 | -181.56M |
March 04, 2024 | -180.56M |
March 01, 2024 | -180.89M |
February 29, 2024 | -182.56M |
February 28, 2024 | -181.40M |
February 27, 2024 | -183.90M |
February 26, 2024 | -184.90M |
February 23, 2024 | -191.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-211.12M
Minimum
Apr 25 2024
100.31M
Maximum
Dec 28 2023
-126.20M
Average
-190.32M
Median
Enterprise Value Benchmarks
Amarin Corp PLC | 44.57M |
Jazz Pharmaceuticals PLC | 10.83B |
Prothena Corp PLC | 612.98M |
Iterum Therapeutics PLC | 20.69M |
GH Research PLC | 446.13M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -59.54M |
Total Expenses (Quarterly) | 58.51M |
EPS Diluted (Quarterly) | -3.567 |
Earnings Yield | -328.6% |